STRIVERDI RESPIMAT Rx
Generic Name and Formulations:
Olodaterol 2.5mcg; per actuation; inhalation spray; contains benzalkonium chloride.
Boehringer Ingelheim Pharmaceuticals
Indications for STRIVERDI RESPIMAT:
Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Limitations of use: not for treating asthma or acute deteriorations of COPD.
Take at same time each day. 2 inh once daily; max 2 inh/24hrs.
LABA use in asthma patients without use of long-term control medication.
LABAs may increase risk of asthma-related death. Do not initiate in patients with acutely deteriorating COPD. Not for relief of acute bronchospasm. Prescribe a short-acting β2-agonist for acute symptoms; monitor for increased need. Do not exceed recommended dose. Not for use with other long-acting β2-agonists. Discontinue if paradoxical bronchospasm or hypersensitivity reactions occur; use alternative therapy. Cardiovascular disease (esp. coronary insufficiency, arrhythmias, hypertrophic obstructive cardiomyopathy, hypertension). Convulsive disorders. Thyrotoxicosis. Prolongation of the QT interval. Hyperresponsiveness to sympathomimetics. Diabetes. Ketoacidosis. Risk of hypokalemia or hyperglycemia. Severe hepatic impairment. Labor & delivery. Pregnancy. Nursing mothers.
Long-acting beta-2 agonist (LABA).
Caution with concomitant other adrenergic drugs. Concomitant xanthine derivatives, steroids, K+-depleting diuretics may potentiate hypokalemia. Extreme caution with MAOIs, tricyclics, or drugs known to prolong QTc interval. Antagonized by β-blockers; if needed, consider cardioselective agents. Potentiated by strong CYP450 and P-gp inhibitors (eg, ketoconazole).
Nasopharyngitis, URTI, bronchitis, UTI, cough, dizziness, rash, diarrhea, back pain, arthralgia.
Inhaler (w. cartridge)—4g (60 inh)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC